Overview
The MSH2 gene serves as the frontline DNA proofreading scout inside dividing cells. Partnering with MSH6 (MutSα) or MSH3 (MutSβ), MSH2 slides along freshly copied DNA helices immediately spotting mismatched nucleotides before recruiting MLH1 and PMS2 to splice out the error.
Along with MLH1, pathogenic germline defects in MSH2 account for the vast majority of Lynch syndrome families—where proactive endoscopy prevents polyps from turning malignant, detailed in our hereditary colon cancer guide.
2p21-p16.3 (Chromosome 2)
Tumor Suppressor & DNA Repair
DNA Mismatch Sensor (MMR)
Lynch syndrome & surveillance
Function of MSH2
Loss of functional MSH2 in a colonic crypt or endometrial lining following a second somatic hit cripples mismatch repair, producing hypermutated microsatellite-instability (MSI-H) tumors—which today actually respond exceptionally well to modern immune checkpoint therapies.
Key Aspects:
🩺 Proactive Colonoscopic Protection
Starting colonoscopies every 1–2 years in early adulthood (age ~20–25) removes adenomas years before invasive carcinoma develops.
🔬 Upstream EPCAM Deletions
In clinical genetics, deletions in the neighboring EPCAM gene can epigenetically silence MSH2, requiring dedicated CNV/MLPA clinical panels beyond basic chips.
🧬 Genetic Variants (SNPs)
While hundreds of rare private variants trigger clinical Lynch syndrome, two common population polymorphisms help separate benign background variants:
2:47414421
Common benign-to-low-effect population polymorphism frequently cited in research studies; does not confer high-penetrance Lynch syndrome.
~9% (Europe)
2:47416342
Mild coding polymorphism classified clinically by InSiGHT/ClinVar as likely benign compared with true truncating MSH2 variants.
~1-2% (Europe)
Practical Significance
✅ Strategies & Guidance
- Map Cancer History: Multiple relatives with colon, uterine, ovarian, stomach, or urinary tract cancers (<50 yrs) justify genetic counseling referral.
- Adhere to Surveillance Intervals: Confirmed carriers follow accelerated gastro/colonoscopy and gynecologic NCCN surveillance schedules.
- Lifestyle Co-Protection: High dietary fiber, avoiding processed red meats, daily movement, and aspirin chemoprevention (only per specialist guidance) support mucosal health.
⚠️ Clinical Notes & Risks
- Extra-Colonic Manifestations: MSH2 carriers face elevated uterine/endometrial, ovarian, gastric, and upper urothelial surveillance considerations.
- Muir-Torre Syndrome Variant: Sebaceous skin neoplasms paired with internal malignancies warrant specialized MMR dermatologic evaluation.
- False-Negative Consumer Tests: Direct-to-consumer microarrays miss almost all pathogenic MSH2 deletions and frameshifts.
📚 Data Sources
- OMIM: #609309 (MutS Homolog 2) & #120435 (Lynch Syndrome I)
- dbSNP & ClinVar: rs2303428, rs4987188, InSiGHT MMR Database
- NCCN / ESMO Guidelines: Hereditary Colorectal & Endometrial Cancer Management
Last Update: November 2026
Related Research Guides for MSH2
Related Genes in Tumor Suppressor
MLH1
MLH1 is a core DNA mismatch repair tumor suppressor that fixes copying errors during cell division.…
TP53
TP53 encodes the p53 protein, one of the most important tumor suppressors, often called the 'guardian…
BRCA1
BRCA1 is a tumor suppressor gene that plays a crucial role in DNA repair and maintaining…